Mapracorat clinical trials
Also written BOL-303242-X and ZK 245186.
How each study uses mapracorat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses mapracorat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- HPA Axis Study in AdultsCompletedPhase 2BayerNCT01408511Written as MapracoratHow we know
- HPA Axis Study in Japanese AdultsCompletedPhase 2BayerNCT01407510Written as MapracoratHow we know
- Dose Escalation of Different Concentrations of ZK 245186 in Atopic DermatitisCompletedPhase 2BayerNCT00944632Written as ZK 245186How we know
- Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract SurgeryCompletedPhase 2Bausch & Lomb IncorporatedNCT00905450Written as BOL-303242-XHow we know
- Mapracorat Ophthalmic Formulation in Subjects With Allergic ConjunctivitisCompletedPhase 2Bausch & Lomb IncorporatedNCT01289431Written as MapracoratHow we know
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01591655Written as MapracoratHow we know
- Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01230125Written as MapracoratHow we know
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01591161Written as MapracoratHow we know
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract SurgeryTerminatedPhase 3Bausch & Lomb IncorporatedNCT01298752Written as MapracoratHow we know
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to MapracoratCompletedPhase 1BayerNCT03399526Written as Mapracorat (ZK 245186, BAY 86-5319)How we know
- Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)CompletedPhase 2BayerNCT01228513Written as ZK245186How we know
- Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)CompletedPhase 2BayerNCT01359787Written as MapracoratHow we know
- Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 DaysCompletedPhase 1Bausch & Lomb IncorporatedNCT01736462Written as MapracoratHow we know
Codes
What other systems call mapracorat · ClinicalTrials.gg INT005556
- UNII (FDA) 145V79YBVPMAPRACORATConfirmed FDA, Wikidata
- Wikidata Q6754194mapracoratConfirmed FDA, Wikidata
- NCI Thesaurus C166458MapracoratOne source FDA
- DrugBank DB12041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 145V79YBVP | MAPRACORAT | Confirmed FDA, Wikidata |
| Wikidata | Q6754194 | mapracorat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166458 | Mapracorat | One source FDA |
| DrugBank | DB12041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.